```html

Drug‑Resistant Tuberculosis (DR‑TB)

Overview

Drug‑resistant tuberculosis (DR‑TB) is a form of pulmonary (or extrapulmonary) tuberculosis that does not respond to the standard first‑line anti‑TB medications—primarily isoniazid and rifampin. When the bacterium Mycobacterium tuberculosis acquires resistance to these drugs, treatment becomes longer, more complex, and often less successful.

Who it affects: DR‑TB can occur in anyone who is infected with TB, but it is more common in:

• People living in or traveling to regions with high rates of drug‑resistant TB (e.g., parts of India, China, Russia, South Africa).
• Individuals with a previous history of TB treatment that was incomplete, irregular, or improperly supervised.
• People with compromised immune systems, such as those living with HIV, diabetes, or receiving immunosuppressive therapy.

Prevalence: According to the World Health Organization (WHO), in 2022 there were an estimated 500,000 cases of rifampicin‑resistant TB worldwide, of which around 78% were multidrug‑resistant TB (MDR‑TB) – resistant to at least isoniazid and rifampin. Extensively drug‑resistant TB (XDR‑TB), which adds resistance to any fluoroquinolone and at least one second‑line injectable, accounted for roughly 6% of MDR‑TB cases (WHO, 2023).

Symptoms

Symptoms of drug‑resistant TB are generally the same as drug‑susceptible TB, but they may persist or worsen despite standard treatment.

Respiratory Symptoms

• Persistent cough – often lasting >3 weeks, may produce sputum or blood.
• Chest pain – worsens with deep breathing or coughing.
• Shortness of breath – progressive, especially if lung tissue is damaged.

Systemic Symptoms

• Fever – low‑grade, often in the evenings.
• Night sweats – soaking the bedclothes.
• Unintended weight loss – “mummified” appearance.
• Fatigue and weakness – may be severe enough to limit daily activities.

Extrapulmonary Manifestations

• Lymph node enlargement – especially cervical nodes.
• Bone and joint pain – spinal (Pott disease) or weight‑bearing joints.
• Kidney or urinary symptoms – hematuria, flank pain.
• Central nervous system involvement – meningitis, seizures, or focal neurologic deficits.

When symptoms continue or reappear after a few weeks of standard therapy, clinicians should suspect drug resistance and order appropriate tests.

Causes and Risk Factors

How resistance develops

Resistance arises when M. tuberculosis is exposed to inadequate drug concentrations—often due to missed doses, poor-quality medication, or incomplete treatment courses. The bacteria mutate, and those that survive become dominant.

Key risk factors

• Previous TB treatment that was irregular, stopped early, or given without proper supervision.
• Close contact with a known DR‑TB case.
• Living in high‑prevalence settings such as overcrowded prisons, refugee camps, or densely populated urban slums.
• HIV infection – immune suppression facilitates both acquisition and progression.
• Diabetes mellitus – impairs immune response.
• Substance abuse (alcohol, tobacco, injectable drugs) – associated with poorer adherence.
• Malnutrition – weakens host defenses.

Diagnosis

Clinical suspicion

Any patient with a history of TB treatment who fails to improve after 2–3 months of therapy, or who relapses shortly after completing treatment, should be evaluated for drug resistance.

Laboratory tests

1. Sputum smear microscopy – quick, but cannot detect resistance.
2. Culture (solid or liquid media) – gold standard for confirming TB and allowing drug‑susceptibility testing (DST); results can take 2–8 weeks.
3. Rapid molecular assays:
   • GeneXpert MTB/RIF – detects TB DNA and rifampin resistance within 2 hours.
   • Line‑probe assays (LPA) – identify mutations conferring resistance to isoniazid and second‑line drugs.
4. Phenotypic DST – performed on cultured isolates to determine minimum inhibitory concentrations for first‑ and second‑line drugs.
5. Whole‑genome sequencing (WGS) – increasingly used in reference labs for comprehensive resistance profiling.

Imaging

• Chest X‑ray – shows infiltrates, cavitations, or fibrosis; may suggest treatment failure.
• CT scan – provides detailed view of cavitary disease, mediastinal lymphadenopathy, or pleural involvement.

Additional assessments

Baseline liver and renal function tests, HIV screening, and diabetes testing are recommended before initiating second‑line therapy.

Treatment Options

Principles

• Use a regimen containing at least four effective drugs to which the isolate is susceptible.
• Treatment duration is longer—generally 18–24 months for MDR‑TB and 24+ months for XDR‑TB.
• Directly Observed Therapy (DOT) or digital adherence technologies are essential to ensure compliance.

First‑line vs. second‑line drugs

Because resistance includes the first‑line agents, therapy relies heavily on second‑line drugs, grouped as follows:

Drug class	Examples	Typical role
Fluoroquinolones	Levofloxacin, Moxifloxacin	Core drug for MDR‑TB
Injectable agents	Amikacin, Kanamycin, Capreomycin	Intensive phase (often 6–8 months)
Injectable‑free regimens	Linezolid, Pretomanid, Bedaquiline	Preferred to avoid hearing loss & kidney toxicity
Other oral agents	Cycloserine, Terizidone, Ethionamide, Clofazimine	Supportive drugs

Newer agents (2020‑2024)

• Bedaquiline – diarylquinoline that targets ATP synthase; improves cure rates when combined with other agents (CDC, 2023).
• Pretomanid – nitroimidazole active against both replicating and non‑replicating bacilli; approved for XDR‑TB regimens.
• Delamanid – similar to pretomanid; used when bedaquiline cannot be given.

Supportive care

• Baseline and periodic monitoring of liver enzymes, kidney function, electrolytes, and auditory testing.
• Nutritional supplementation (protein, vitamins A, D, zinc) to aid host immunity.
• Management of comorbidities (HIV antiretroviral therapy, diabetes control).
• Psychosocial support, counseling, and adherence incentives.

Living with Drug‑Resistant Tuberculosis

Medication adherence

• Take drugs exactly as prescribed—never skip a dose.
• Use a pill organizer, alarms, or smartphone apps to remind you.
• Participate in DOT or video‑observed therapy if offered.

Managing side effects

• Nausea/vomiting – take meds with food (if allowed), sip clear fluids, discuss anti‑emetics with your doctor.
• Peripheral neuropathy (from linezolid or cycloserine) – vitamin B6 supplementation may help.
• Hearing loss (injectables) – baseline and quarterly audiograms; switch to injectable‑free regimen if possible.
• QT prolongation (bedaquiline, fluoroquinolones) – avoid other QT‑prolonging drugs, limit caffeine/alcohol, get regular ECGs.

Daily life & work

• Most patients can continue work once they are no longer infectious (usually after 2 weeks of effective therapy and a negative sputum smear).
• Inform close contacts and follow infection‑control advice (cover mouth when coughing, use masks in crowded indoor settings).
• Maintain a balanced diet, stay hydrated, and engage in light exercise as tolerated.

Emotional well‑being

Long treatment courses can be isolating. Seek peer‑support groups, counseling, or community health‑worker visits. Mental health conditions such as depression are common and treatable.

Prevention

• Vaccination – BCG vaccine offers limited protection against pulmonary TB in adults but can prevent severe disseminated disease in children.
• Early detection and treatment of drug‑susceptible TB – prevents the emergence of resistance.
• Adherence support – directly observed therapy, patient‑centred counselling, and socioeconomic assistance.
• Infection control – proper ventilation, ultraviolet germicidal irradiation in high‑risk settings, use of N95 respirators for healthcare workers.
• Screening of contacts – anyone living with a DR‑TB patient should undergo symptom review and, if indicated, GeneXpert testing.
• Address comorbidities – HIV testing and treatment, diabetes management, smoking cessation.

Complications

If left untreated or inadequately treated, DR‑TB can lead to serious, sometimes fatal, outcomes:

• Progressive lung destruction – cavitation, fibrosis, and bronchiectasis causing chronic respiratory insufficiency.
• Hemoptysis – massive bleeding from eroded blood vessels.
• Disseminated (miliary) TB – spread to multiple organs, leading to organ failure.
• TB meningitis – high mortality and risk of permanent neurological deficits.
• Drug toxicity – severe liver injury, renal failure, ototoxicity, or bone marrow suppression.
• Psychosocial impact – loss of employment, stigma, and mental health disorders.

When to Seek Emergency Care

For all other concerns, contact your healthcare provider or TB clinic promptly. Early intervention improves outcomes and reduces transmission.

---

Sources: World Health Organization (2023) Global Tuberculosis Report; Centers for Disease Control and Prevention (2023) Drug‑Resistant TB Fact Sheet; Mayo Clinic (2024) Tuberculosis – Treatment; National Institutes of Health (2022) Clinical Guidelines for MDR‑TB; Cleveland Clinic (2023) Managing Side Effects of TB Medications.

```